Kiniksa Pharmaceuticals International (KNSA) Other Non Operating Income (2022 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Other Non Operating Income came in at $4.0 million in Q2 2026, up 45.42% YoY from $2.7 million in Q2 2025, and up 15.73% on a QoQ basis from $3.4 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Other Non Operating Income (2022 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 5 years of Other Non Operating Income data on file, last reported at $4.0 million in Q2 2026.
- Quarterly Other Non Operating Income rose 45.42% year-over-year to $4.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $14.0 million (up 43.07% YoY) and the FY2025 annual result came in at $11.6 million, up 23.07% from the prior year.
- Other Non Operating Income climbed to $4.0 million in Q2 2026, from $3.4 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $4.0 million in Q2 2026 to a low of $34000.0 in Q1 2022.
- A 5-year average of $2.1 million and a median of $2.3 million in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 5288.24% — and 2024, when it retreated 2.07%.
- Tracing KNSA's Other Non Operating Income over 5 years: stood at $794000.0 in 2022, then surged by 198.36% to $2.4 million in 2023, then fell by 2.07% to $2.3 million in 2024, then jumped by 50.91% to $3.5 million in 2025, then advanced by 12.85% to $4.0 million in 2026.
- The last three Other Non Operating Income figures came in at $4.0 million (Q2 2026), $3.4 million (Q1 2026), and $3.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.56 Bn | 220.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.95 Mn |
| Mar 31, 2026 | 3.41 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Sep 30, 2025 | 3.14 Mn |
| Jun 30, 2025 | 2.72 Mn |
| Mar 31, 2025 | 2.29 Mn |
| Dec 31, 2024 | 2.32 Mn |
| Sep 30, 2024 | 2.46 Mn |
| Jun 30, 2024 | 2.42 Mn |
| Mar 31, 2024 | 2.27 Mn |
| Dec 31, 2023 | 2.37 Mn |
| Sep 30, 2023 | 2.43 Mn |
| Jun 30, 2023 | 1.92 Mn |
| Mar 31, 2023 | 1.83 Mn |
| Dec 31, 2022 | 794,000.00 |
| Sep 30, 2022 | 322,000.00 |
| Jun 30, 2022 | 103,000.00 |
| Mar 31, 2022 | 34,000.00 |